SynAct Pharma

SynAct Pharma is a clinical-stage biotechnology company focussed on the development of treatments to resolve, rather than inhibit, ongoing inflammatory processes in acute and chronic diseases.

Equities

Equities by Sector

Sectors

Thematics

Latest

Digital assets – Part 5: Digital asset treasury companies

Edison explains: UK Budget – Why the market rallied despite the tax grab

Digital assets – Part 4: Asset tokenisation and payments

Audiovisual

Latest

Ajax Resources – executive interview

The Law Debenture Corporation – equity proposition

Take on Trusts – November 2025

About Edison

About Edison

Careers

SynAct Pharma (STO: SYNACT)

Latest News

Latest Insights

SynAct Pharma (STO: SYNACT) confirms recruitment on-track in RA trial

SynAct Pharma — Approaching a catalyst-rich period

SynAct Pharma — Differentiated inflammation resolution approach

SynAct Pharma – executive interview

Sector

Equity Analyst

Key Management

Research

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time